Medicine
Twirla 2.3 mg/2.6 mg transdermal patch
Twirla 2.3 mg/2.6 mg transdermal patch is a prescription medicine containing Ethinyl estradiol and Levonorgestrel for transdermal use, marketed by Agile Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store at room temperature 20°C to 25°C (68°F to 77°F) with excursions…
Key facts
- Active ingredient (INN)
- Ethinyl estradiol and Levonorgestrel
- Brand
- Twirla
- Strength
- 2.3 mg/2.6 mg
- Dosage form
- Transdermal patch
- Route
- Transdermal
- Packs
- 1 pouch, 3 pouches
- Marketing authorisation holder
- Agile Therapeutics
- Manufacturer
- Agile Therapeutics
- Origin register
- US FDA, United States
- Storage
- Store at room temperature 20°C to 25°C (68°F to 77°F) with excursions permitted 15°C to 30°C (59°F to 86°F). Store in original unopened pouch.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- HS code (indicative)
- 3004.39Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 11 September 2020
- Identifiers
- RxCUI 2396242, 2396253, 2396258 +1DailyMed set ID bcaf8db0-1750-425d-b008-255b5e7a9cc6NDC 71671-100Application NDA204017
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 pouch in 1 carton / 1 patch in 1 pouch | 71671-100-01 | Agile Therapeutics | 11 September 2020 |
| 3 pouch in 1 carton / 1 patch in 1 pouch | 71671-100-03 | Agile Therapeutics | 11 September 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
| Register | Status | Source |
|---|---|---|
| US FDA | Listed, marketed | Source record for this pageChecked 12 November 2026 |
| US FDA | First approved 10 May 1982 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Ethinyl estradiol and Levonorgestrel
Clinical summary
Ethinyl estradiol and Levonorgestrel is a fixed-dose combination of an estrogen, a progestin and a progestin-containing intrauterine system indicated by females of reproductive potential to prevent pregnancy. MedsAcross supplies Ethinyl estradiol and Levonorgestrel for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Ethinyl estradiol and LevonorgestrelFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- levonorgestrel and ethinyl estradiol prescribing information (Acella Pharmaceuticals) · U.S. National Library of Medicine, DailyMed
Need Twirla 2.3 mg/2.6 mg transdermal patch for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.